Suzhou Bowa Sunshine

Suzhou Bowa Sunshine Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for oncology. Headquartered in the Suzhou Industrial Park, the company specializes in 'synthetic lethality' and DNA damage repair (DDR) pathways to treat various cancers. Its lead candidate, BW-101, is a selective USP1 inhibitor currently undergoing clinical evaluation for advanced solid tumors, including ovarian and breast cancers. Bowa Sunshine leverages its internal R&D capabilities to design highly selective therapeutics with improved safety profiles. The company is supported by prominent venture capital firms and aims to address significant unmet medical needs in the global oncology market.